Epsilogen: co-opting IgE antibodies against cancer

Epsilogen leverages natural high affinity of IgE for immune cells to target solid tumors

Epsilogen is taking a long overlooked isotype of human antibodies -- the IgE class -- and leveraging their high affinity for immune effector cells to seek out and destroy solid tumors.

“What we are doing is we are redirecting the tropism of a major arm of the immune system,” CEO Tim Wilson told BioCentury.

Nearly all mAb therapeutics are based on the IgG class, and for good reasons. Wilson said the early mAb pioneers preferred IgG because it has a long half-life in serum, ranging from two to three weeks, and is the easiest to manipulate

Read the full 957 word article

How to gain access

Continue reading with a
two-week free trial.